AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31065301
Drug: Probiotics added
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics added to antimicrobial treatment
Trial: 31065624
Drug: Molecularly tailored
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecularly tailored therapy
Trial: 31066879
Drug: Implementation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation of prehospital TBI guidelines emphasizing avoidance/treatment of hypoxia, prevention/correction of hyperventilation, and avoidance/treatment of hypotension
Trial: 31067538
Drug: Proton Pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton Pump Inhibitor (PPI) treatment for 2 months
Trial: 31067538
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of PPI treatment
Trial: 31067570
Drug: Donor-derived HCMV-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donor-derived HCMV-specific cytotoxic T cells (CTLs) as first-line therapy
Trial: 31068222
Drug: Modified FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified FOLFIRINOX regimen (intravenous infusion of oxaliplatin, 65 mg/m2)
Trial: 31068369
Drug: STM 434
RxNorm normalized name: STM 217
DrugBank: STM-217 (DB17358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STM 434 (0.25 mg/kg every 4 weeks to 8 mg/kg every 2 weeks)
Trial: 31072394
Drug: Future therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Future therapeutic HIV vaccine
Trial: 31073292
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise as add-on treatment, details on dosage and duration not available
Trial: 31074004
Drug: Tissue transglutaminase
RxNorm normalized name: Tissue transglutaminase IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue transglutaminase antibody levels
Trial: 31075727
Drug: Dose-dense epirubicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense epirubicin, paclitaxel and cyclophosphamide (EPC)
Trial: 31075727
Drug: Dose-dense epirubicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense epirubicin, cyclophosphamide, paclitaxel and capecitabine (EC-PwX)
Trial: 31076409
Drug: Oral lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral lenalidomide 10 mg daily starting on day 9 of cycle 1 and IV rituximab 375 mg/m2
Trial: 31076416
Drug: Prediabetes (IGT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediabetes (IGT or IFG) after revascularization, optimal medical therapy, or both
Trial: 31077039
Drug: High-dose α-tocopherol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose α-tocopherol, N-acetylcysteine, and α-lipoic acid in combination
Trial: 31077164
Drug: Bevacizumab combined
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab combined with platinum-doublet chemotherapy
Trial: 31077529
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (continuous subcutaneous insulin infusion for 7 days)
Trial: 31079357
Drug: Teneligliptin 20
RxNorm normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Teneligliptin 20 mg qd for 12 weeks
Trial: 31081020
Drug: 8-hourly lopinavir/ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-hourly lopinavir/ritonavir dosing strategy
Trial: 31678203
Drug: Magnetically assisted
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetically assisted capsule endoscopy (MACE)
Trial: 31082688
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitors (TKIs) with or without chemotherapy
Trial: 31084325
Drug: Aspirin, Warfarin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, Warfarin, DOAC
Trial: 31085605
Drug: iReadMore therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iReadMore therapy (a therapy app for reading training)
Trial: 31085763
Drug: Combination BRAF
RxNorm normalized name: Braftovi
DrugBank: Encorafenib (DB11718)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combination BRAF and MEK inhibition
Trial: 31085763
Drug: Cabozantinib therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib therapy
Trial: 31086307
Drug: 160 L alglucosidase
RxNorm normalized name: Alglucosidase Alfa
DrugBank: Alglucosidase alfa (DB01272)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 160 L alglucosidase alfa
Trial: 31087382
Drug: HBsAg vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBsAg vaccine (Engerix-B) as challenge dose
Trial: 31087457
Drug: Buccal bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal bone loss
Trial: 31087772
Drug: Locoregional therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional therapies (LRT)
Trial: 31088809
Drug: Acalabrutinib 100
RxNorm normalized name: acalabrutinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib 100 mg twice daily or 200 mg once daily
Trial: 31088831
Drug: Erdafitinib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdafitinib (oral pan-FGFR inhibitor)
Trial: 31089278
Drug: Bu-Oral (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bu-Oral (oral busulfan)
Trial: 31089278
Drug: Bu-IV (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bu-IV (intravenous busulfan)
Trial: 31089689
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin A supplement (1.0 μmol [14,15]-13C2-retinyl acetate)
Trial: 31089689
Drug: Routine 200,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine 200,000 IU vitamin A capsule administered after RID test
Trial: 31089689
Drug: Receiving 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receiving 2 or 3 vitamin A supplements in the past 12 months
Trial: 31090044
Drug: Sarilumab 150
RxNorm normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 150 mg subcutaneously every 2 weeks for 24 weeks
Trial: 31090044
Drug: Sarilumab 200
RxNorm normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 200 mg subcutaneously every 2 weeks for 24 weeks
Trial: 31092022
Drug: AFEQT subscale
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFEQT subscale Activities of Daily Living
Trial: 31095609
Drug: Hypoalbuminemia (P-Alb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoalbuminemia (P-Alb < 34g/L)
Trial: 31095609
Drug: Normal albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal albumin levels (P-Alb ≥ 34g/L)
Trial: 31096006
Drug: Direct-acting antiviral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antiviral (DAA) therapy with sustained virologic response (SVR)
Trial: 31096937
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (AA) at 1.5 g/kg/day, days 1-3, with mFOLFOX6 or FOLFIRI
Trial: 31096937
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (AA) at 0.2-1.5 g/kg, 3-h infusion, once daily, days 1-3, with mFOLFOX6 or FOLFIRI
Trial: 31096944
Drug: Multifaceted community-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted community-based intervention including parent workshops on nutrition and physical activity, school-based nutrition lessons, enhanced physical education, and monthly vouchers for fruits and vegetables.
Trial: 31096979
Drug: Dienogest (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dienogest (2 mg/daily)
Trial: 31097024
Drug: Intermittent nivolumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent nivolumab for 12 weeks; 5 patients (36%) met criteria for intermittent phase with a median tumor burden decrease of 46%; all agreed to intermittent therapy.
Trial: 31097024
Drug: Intermittent nivolumab;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent nivolumab; acceptance rate for intermittent therapy was 100% among those eligible (5 out of 5).
Trial: 31097294
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (10 mg/70 kg)
Trial: 31097487
Drug: Rotavirus vaccine
RxNorm normalized name: rotavirus vaccine
DrugBank: Rotavirus vaccine (DB10276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotavirus vaccine introduction
Trial: 31099252
Drug: AMD11070 (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMD11070 (an orally administered CXCR4 entry inhibitor)
Trial: 31099895
Drug: CYP450 activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP450 activities assessed after a single oral administration of a cocktail of probe drugs
Trial: 31100456
Drug: Remission-time equivalents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remission-time equivalents (RTE) for symptom severity or treatment-related risk
Trial: 31101422
Drug: emm75 GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: emm75 GAS doses applied by swab to the pharynx
Trial: 31101422
Drug: Antibiotics treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics treatment for all participants
Trial: 31101489
Drug: Polatuzumab vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polatuzumab vedotin in combination with R-CHP (cyclophosphamide, doxorubicin, prednisone)
Trial: 31101489
Drug: Polatuzumab vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polatuzumab vedotin in combination with G-CHP (obinutuzumab, cyclophosphamide, doxorubicin, prednisone)
Trial: 31101577
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (1 to 5 mg daily)
Trial: 31102044
Drug: Full-mouth disinfection
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-mouth disinfection (FMD) protocol including full-mouth scaling and root planing within 24 hours, application of chlorhexidine digluconate (CHX) gel in pockets and tongue plus CHX rinses for 14 days
Trial: 31102143
Drug: Immuno-Oncology (IO)
RxNorm normalized name: Io-Shield
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immuno-Oncology (IO) treatments
Trial: 31102144
Drug: OnabotulinumtoxinA 155
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: OnabotulinumtoxinA 155 U administered every 12 weeks
Trial: 31104505
Drug: No migraine-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No migraine-specific rescue medication
Trial: 31106898
Drug: Hydroxyurea, single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea, single oral dose of 20 mg/kg, followed by PK-guided dosing
Trial: 31106898
Drug: Hydroxyurea, PK-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea, PK-guided dosing
Trial: 31106898
Drug: Traditional weight-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional weight-based dosing
Trial: 31107260
Drug: Closed-loop (CL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop (CL) system for propofol administration with BIS target between 40 and 50
Trial: 31107300
Drug: Non-nucleoside reverse
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-nucleoside reverse transcriptase inhibitors
Trial: 31107300
Drug: Integrase inhibitors
RxNorm normalized name: Integrase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrase inhibitors (yes or no)
Trial: 31107869
Drug: Triple-drug therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-drug therapy (IVM + DEC + ALB)
Trial: 31108163
Drug: Clinician-administered KSADS-COMP
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician-administered KSADS-COMP
Trial: 31108163
Drug: Youth self-administered
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Youth self-administered KSADS-COMP
Trial: 31108163
Drug: Parent self-administered
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent self-administered KSADS-COMP
Trial: 31108510
Drug: ITF-rich vegetables
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITF-rich vegetables (15 g ITF/d)
Trial: 31110648
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone 400 mg daily at bedtime from 28 weeks until delivery
Trial: 31110648
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment other than normal tonics)
Trial: 31111867
Drug: Salt intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt intake 1 g/d higher in Japan
Trial: 31111867
Drug: Salt intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt intake 1 g/d higher in China
Trial: 31111867
Drug: Salt intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt intake 1 g/d higher in the United Kingdom
Trial: 31111867
Drug: Salt intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt intake 1 g/d higher in the United States
Trial: 31112476
Drug: Nivolumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab monotherapy followed by N-AVD (doxorubicin, vinblastine, and dacarbazine)
Trial: 31112476
Drug: Nivolumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab monotherapy followed by N-AVD
Trial: 31113467
Drug: Serum Cyr61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum Cyr61 concentration at baseline and 12 weeks after treatment in ACR responders
Trial: 31113467
Drug: Serum Cyr61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum Cyr61 concentration at baseline and 12 weeks after treatment in non-responders
Trial: 31113837
Drug: Intravenous CPX-POM
RxNorm normalized name: CPX
DrugBank: DPCPX (DB12946)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous CPX-POM
Trial: 31113837
Drug: Oral CPX-O
RxNorm normalized name: Padimate O
DrugBank: Padimate O (DB11570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral CPX-O
Trial: 31114268
Drug: Grazoprevir/elbasvir in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grazoprevir/elbasvir in combination with peginterferon alfa plus ribavirin
Trial: 31114846
Drug: Emactuzumab monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emactuzumab monotherapy
Trial: 31114846
Drug: Emactuzumab in
RxNorm normalized name: Emactuzumab
DrugBank: Emactuzumab (DB14905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emactuzumab in combination with paclitaxel (80 mg/m2 weekly)
Trial: 31114846
Drug: Emactuzumab (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emactuzumab (1000 mg every 2 weeks)
Trial: 31114846
Drug: Emactuzumab (monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emactuzumab (monotherapy and combination)
Trial: 31116389
Drug: Enoxaparin, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin, 40 mg per day
Trial: 31116389
Drug: Real-time enoxaparin
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Real-time enoxaparin dose adjustment
Trial: 31116405
Drug: Ovarian tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovarian tissue transplantation (OTT) after prior chemotherapy exposure
Trial: 31116676
Drug: Anticoagulant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant therapy (initiated in 675 patients, 97%); 600 (89%) treated with low-molecular-weight heparin
Trial: 31118445
Drug: LDL-c <2.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-c <2.6 mmol/L
Trial: 31118571
Drug: 60-mg dexlansoprazole
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-mg dexlansoprazole
Trial: 31118571
Drug: 40-mg esomeprazole
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-mg esomeprazole
Trial: 31120195
Drug: Doravirine 100
RxNorm normalized name: doravirine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doravirine 100 mg coadministered with methadone
Trial: 31120355
Drug: Palbociclib at
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib at 75 mg, 100 mg, or 125 mg on days 1-12 of each 21-day cycle plus intravenous bortezomib 1.0 mg/m²
Trial: 31120585
Drug: Auto-titration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auto-titration of EPAP during NIV
Trial: 31121319
Drug: SRH (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRH (blood glucose≥11mmol/L in at least two samples during the first 3 days)
Trial: 31122213
Drug: Circulating 25-hydroxyvitamin
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Circulating 25-hydroxyvitamin D levels above 50 nmol/L (sufficient)
Trial: 31122213
Drug: Circulating 25-hydroxyvitamin
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Circulating 25-hydroxyvitamin D levels below 50 nmol/L (insufficient)
Trial: 31122988
Drug: Assessment for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment for osteonecrosis using MRI scans of the lower limbs and physiotherapy assessment at various time points (within 4 weeks of diagnosis, end of delayed intensification, and 1, 2, and 3 years after the start of maintenance therapy)
Trial: 31124321
Drug: Levetiracetam Monotherapy
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam Monotherapy
Trial: 31124335
Drug: Osimertinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib treatment in T790M-positive tissue (n=45)
Trial: 31124335
Drug: Osimertinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib treatment in T790M-positive plasma (n=54)
Trial: 31124471
Drug: Game play
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Game play with treatment as usual
Trial: 31124580
Drug: Selinexor 60
RxNorm normalized name: selinexor 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor 60 mg, carfilzomib 20/27 mg/m², dexamethasone (SKd)
Trial: 31125423
Drug: Pazopanib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 600 mg with food
Trial: 31125423
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg fasted
Trial: 31126257
Drug: Controls (women
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controls (women surgically intervened for breast augmentation or reduction)
Trial: 31126287
Drug: Previous users
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous users of inhalation therapy
Trial: 31126332
Drug: Nintedanib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib (200 mg/bid) plus letrozole (2.5 mg/day)
Trial: 31126575
Drug: CAM treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAM treatments (Acupuncture, Reflexology, Guided Imagery)
Trial: 31127700
Drug: Antidepressants and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants and antiepileptics
Trial: 31128146
Drug: Pencil beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pencil beam scanning proton beam radiation therapy (PBS-PT) with concurrent 5-fluorouracil (5-FU) and mitomycin C (MMC)
Trial: 31128285
Drug: Cephalosporins (monotherapy)
RxNorm normalized name: Cephalosporium roseum
DrugBank: Cephalosporium roseum (DB10932)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalosporins (monotherapy)
Trial: 31128285
Drug: Tetracycline (monotherapy)
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline (monotherapy)
Trial: 31128285
Drug: Macrolide (monotherapy)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macrolide (monotherapy)
Trial: 31128285
Drug: Cotrimoxazole (monotherapy)
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole (monotherapy)
Trial: 31128285
Drug: Quinolones plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinolones plus carbapenems (combination therapy)
Trial: 31128285
Drug: Quinolones (sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinolones (sequential therapy)